Future Directions in Neuropathic Pain Therapy: Closing the Translational Loop
Future Directions in Neuropathic Pain Therapy: Closing the Translational Loop
复制标题
DOI：
10.1634/theoncologist.2009-s502
复制
发表时间：
2010-05-01
期刊：
影响因子：
5.8
通讯作者：
Woolf, Clifford J.
中科院分区：
文献类型：
--
作者：
Backonja, Miroslav;Woolf, Clifford J.
在大多数患者中，现有的神经病理性疼痛治疗方法远未奏效。此外，目前所有的治疗方法都是对症治疗，而不是改善疾病或治愈疾病。针对各种机制的一系列治疗方式正在涌现，但选择最佳目标并评估针对多种类型的神经病理性疼痛障碍的治疗并不是一项容易的任务。在这篇文章中，我们建议将药物发现范式的重点转向对导致个体患者神经病理性疼痛的特定神经生物学机制的公正评估。应该优先考虑全基因组关联研究和其他发现科学方法，以确定重要的新靶点，以及开发越来越复杂的工具来测量和分类神经病理性疼痛。《肿瘤学家》2010；15(增刊2)：24-29
In the majority of patients, existing therapies for neuropathic pain are far from effective. Furthermore, all current treatments are symptomatic rather than disease-modifying or curative. A range of therapeutic modalities is emerging, targeting a variety of mechanisms, but choosing the best target and evaluating the resulting therapies against the many types of neuropathic pain disorders is not an easy task. In this article, we suggest a shift in emphasis of the drug discovery paradigm toward unbiased evaluation of the particular neurobiological mechanisms contributing to neuropathic pain in individual patients. Genomewide association studies and other discovery science approaches to identify significant novel targets should be given priority as should the development of increasingly sophisticated tools for measuring and categorizing neuropathic pain. The Oncologist 2010; 15(suppl 2): 24-29